ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.000
-0.050 (-2.44%)
Aug 28, 2026, 4:00 PM EDT - Market closed
ALX Oncology Holdings Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
48
Market Cap
276.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Invivyd | 58.37M |
| AC Immune | 21.67M |
| Lineage Cell Therapeutics | 13.08M |
| Surrozen | 11.51M |
| Pyxis Oncology | 11.04M |
| Whitehawk Therapeutics | 7.15M |
| Fate Therapeutics | 6.49M |
ALXO News
- 24 days ago - ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 24 days ago - ALX Oncology Holdings Earnings release: Q2 2026 - Filings
- 24 days ago - ALX Oncology Holdings Quarterly report: Q2 2026 - Filings
- 2 months ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 2 months ago - ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds - TheFly
- 2 months ago - ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel - GlobeNewsWire
- 2 months ago - ALX Oncology Holdings Transcript: AGM 2026 - Transcripts
- 3 months ago - ALX Oncology Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts